• 1
    Dave JA, Engel ME, Freercks R et al. Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. QJM 2010; 103:495503.
  • 2
    Matz K, Keresztes K, Tatachl C et al. Disorders of glucose metabolism in acute stroke patients. Diabetes Care 2006; 29:792797.
  • 3
    Kernan WM, Viscoli CM, Inzucchi SE et al. Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med 2005; 165:227233.
  • 4
    Vermeer SE, Sandee W, Algra A, Koudstaal PJ, Kappelle LJ, Dippel DW. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Dutch TIA Trial Study Group. Stroke 2006; 37:14131417.
  • 5
    Jia Q, Zheng H, Zhao X et al. Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke 2012; 43:650657.
  • 6
    Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2012; 344:e3564.
  • 7
    Defronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerosis. Diabetes Care 1997; 50:191197.
  • 8
    Steinberg HO, Chaker J, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97:26012610.
  • 9
    van Loon BJP. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 1993; 42:945949.
  • 10
    Gillies CL, Abrahams K, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334:299308.
  • 11
    The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:10961105.
  • 12
    Lilly M, Godwill M. Treating prediabetes with metformin. Systematic review and meta-analysis. Can Fam Physician 2009; 55:363369.
  • 13
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393403.
  • 14
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854865.
  • 15
    Kooy A, de Jager J, Lehert P et al. Long-term effects of metfomin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 23:616625.
  • 16
    van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604607.
  • 17
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012 Suppl 1:S6471.
  • 18
    Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:227276.
  • 19
    Kernan WN, Inzucchi SE, Viscoli CM et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34:14313146.
  • 20
    Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366:12791289.
  • 21
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:11801188.
  • 22
    Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:33493354.
  • 23
    Shar P, Meduliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010; 9:347354.
  • 24
    Hopper IK, Billah B, Skiba MA, Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with impaired glucose tolerance: meta-analysis of randomized controlled clinical trials. Circulation 2010; 122:A15435.
  • 25
    NAVIGATOR Study Group, Holman RR, Haffner SM et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:14631476.